专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5965536A Methods of inhibiting CXC intercrine molecules 失效
标题翻译：抑制CXC分泌分子的方法
公开(公告)号：US5965536A
公开(公告)日：1999-10-12
申请号：US666564
申请日：1996-06-14
申请人： Allen Barry Cohen, deceased , Edmund J. Miller , Shinichiro Hayashi , Anna K. Kurdowska , Ronald R. Tuttle
发明人： Allen Barry Cohen, deceased , Edmund J. Miller , Shinichiro Hayashi , Anna K. Kurdowska , Ronald R. Tuttle
IPC分类号： A61K38/00 , C07K7/06 , C07K14/54 , A61K38/02 , C07K5/00 , C07K7/00
CPC分类号： C07K7/06 , C07K14/54 , C07K14/5421 , A61K38/00
摘要： Disclosed are methods for inhibiting and modulating the actions of CXC intercrine molecules. The antileukinate peptides described inhibit IL-8, GRO and MIP2.beta. binding to neutrophils and neutrophil activation. The peptides are particularly advantageous as they inhibit IL-8-induced enzyme release at a 25 fold lower concentration than is required to inhibit chemotaxis, which makes them ideal for treating various inflammatory diseases and disorders including, amongst others, Adult Respiratory Distress Syndrome (ARDS), cystic fibrosis and chronic bronchitis.
摘要翻译： PCT No.PCT / US93 / 12245 Sec。 371日期1996年6月14日第 102（e）日期1996年6月14日PCT提交1993年12月15日PCT公布。出版物WO95 / 16702 日期：1995年6月22日被公开是用于抑制和调节CXC胞间分子作用的方法。所描述的抗白细胞介素肽抑制IL-8，GRO和MIP2β与嗜中性粒细胞和嗜中性粒细胞活化的结合。这些肽是特别有利的，因为它们以比抑制趋化性所需的浓度低25倍抑制IL-8诱导的酶释放，这使得它们是治疗各种炎性疾病和病症的理想选择，包括成人呼吸窘迫综合征（ARDS）），囊性纤维化和慢性支气管炎。

2. 发明授权

US5888978A Method for reducing the severity of gastro-intestinal damage 失效
标题翻译：降低胃肠损伤严重程度的方法
公开(公告)号：US5888978A
公开(公告)日：1999-03-30
申请号：US527252
申请日：1995-09-12
申请人： Beverly E. Girten , Paul Omholt , Ronald R. Tuttle
发明人： Beverly E. Girten , Paul Omholt , Ronald R. Tuttle
IPC分类号： A61K38/00 , A61K38/04 , A61K38/07 , A61K38/08 , A61K38/12 , A61P1/00 , A61P43/00 , C07K5/117 , C07K5/12 , C07K7/06 , C07K5/10
CPC分类号： A61K38/08 , A61K38/04 , A61K38/07 , A61K38/12
摘要： The present invention provides methods for reducing the severity of GI damage in an individual by administering a cytokine regulatory agent to an individual that is susceptible to developing such damage.
摘要翻译：本发明提供了通过向容易发生此类损伤的个体施用细胞因子调节剂来降低个体的GI损伤的严重性的方法。

3. 发明授权

US5741774A Use of a cytokine regulatory agent to treat rheumatoid arthritis 失效
标题翻译：使用细胞因子调节剂治疗类风湿关节炎
公开(公告)号：US5741774A
公开(公告)日：1998-04-21
申请号：US722279
申请日：1996-09-27
申请人： Beverly E. Girten , Ronald R. Tuttle
发明人： Beverly E. Girten , Ronald R. Tuttle
IPC分类号： A61K38/00 , A61K38/08 , C07K5/117 , C07K14/68 , C07K14/685 , C07K14/695 , C07K5/00 , C07K7/00 , C07K17/00
CPC分类号： C07K14/68 , A61K38/08 , C07K14/685 , C07K14/695 , C07K5/1024
摘要： The present invention relates to the use of a cytokine regulatory agent to reduce the severity of rheumatoid arthritis.
摘要翻译：本发明涉及细胞因子调节剂降低类风湿性关节炎的严重程度的用途。

4. 发明授权

US5643967A Growth promotion 失效
公开(公告)号：US5643967A
公开(公告)日：1997-07-01
申请号：US37789
申请日：1993-03-18
申请人： David B. Anderson , Klaus K. Schmiegel , Edward L. Veenhuizen , Ronald R. Tuttle
发明人： David B. Anderson , Klaus K. Schmiegel , Edward L. Veenhuizen , Ronald R. Tuttle
IPC分类号： A23K1/16 , A61K31/135 , C07C51/347 , C07C51/487 , C07C215/30 , C07C217/62
CPC分类号： C07C217/62 , A23K20/111 , A61K31/135 , C07C215/30 , C07C51/347 , C07C51/487
摘要： .beta.-Phenethanolamines are effective in promoting growth and improving feed efficiency and leanness in animals.

5. 发明授权

US5234404A Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist 失效
标题翻译：通过使用运动模拟剂β激动剂的闭环药物递送的运动模拟来诊断，评估和治疗冠状动脉疾病
公开(公告)号：US5234404A
公开(公告)日：1993-08-10
申请号：US775735
申请日：1991-10-11
申请人： Ronald R. Tuttle , Clinton E. Browne, III
发明人： Ronald R. Tuttle , Clinton E. Browne, III
IPC分类号： A61K31/135 , A61K31/16 , A61N1/32 , C07C45/30 , C07C215/60 , C07C217/62 , C07C237/30
CPC分类号： C07C237/30 , A61K31/135 , A61K31/16 , A61N1/044 , A61N1/325 , C07C215/60 , C07C217/62 , C07C45/305 , A61N1/0448
摘要： Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.
摘要翻译：用于通过递送运动模拟剂的闭环药物递送系统来诊断，评估和治疗冠状动脉疾病（CAD）的方法和装置，包括引起急性和适应性心血管反应的新型运动模拟剂，其类似于那些提供有氧活动引发的。对运动模拟剂的急性反应用于诊断和评估CAD，代替对有氧运动的急性反应。由于其适应性反应，这些化合物可用于治疗CAD以代替由有氧运动训练引起的适应性反应或治疗其中需要有氧运动引起的适应性反应的其他状况。

6. 发明授权

US4849453A Growth promotion 失效
标题翻译：成长促进
公开(公告)号：US4849453A
公开(公告)日：1989-07-18
申请号：US153640
申请日：1988-02-08
申请人： David B. Anderson , Klaus K. Schmiegel , Edward L. Veenhuizen , Ronald R. Tuttle
发明人： David B. Anderson , Klaus K. Schmiegel , Edward L. Veenhuizen , Ronald R. Tuttle
IPC分类号： A23K1/16 , A61K31/135 , C07C51/347 , C07C51/487 , C07C215/30 , C07C217/62
CPC分类号： C07C217/62 , A23K20/111 , A61K31/135 , C07C215/30 , C07C51/347 , C07C51/487
摘要： .beta.-Phenethanolamines are effective in promoting growth and improving feed efficiency and leanness in animals.
摘要翻译： β-苯乙醇胺有效促进生长，提高动物的饲料效率和瘦肉。

7. 发明授权

US5726156A Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels 失效
标题翻译：细胞因子调节剂和与改变的细胞因子水平相关的病理学和病症中使用的方法
公开(公告)号：US5726156A
公开(公告)日：1998-03-10
申请号：US527056
申请日：1995-09-12
申请人： Beverly E. Girten , Ali Andalibi , Amaresh Basu , Patrick Fagan , Richard A. Houghten , Costas C. Loullis , Paul Omholt , Ronald R. Tuttle , Mark J. Suto , Patricia A. Weber
发明人： Beverly E. Girten , Ali Andalibi , Amaresh Basu , Patrick Fagan , Richard A. Houghten , Costas C. Loullis , Paul Omholt , Ronald R. Tuttle , Mark J. Suto , Patricia A. Weber
IPC分类号： A61K38/00 , A61K45/00 , A61P3/00 , A61P3/08 , A61P3/10 , A61P9/00 , A61P11/00 , A61P13/02 , A61P15/00 , A61P29/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07K5/087 , C07K5/117 , C07K5/12 , C07K7/06 , C07K7/64 , C07K14/68 , C07K14/695
CPC分类号： C07K14/695 , C07K14/68 , C07K5/0812 , C07K5/1024 , A61K38/00
摘要： The present invention relates to novel peptides that are potent cytokine regulatory agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine regulatory agent. Administration of such a cytokine regulatory agent to a subject can enhance or restrain cytokine activity. Thus, the present invention provides a method of regulating cytokine activity in a subject having a condition characterized by aberrant or altered cytokine activity. The invention also provides methods of treating such conditions, including, for example, disuse deconditioning, diseases mediated by nitric oxide and cytokines, adverse drug reactions, obesity, septic shock, and adverse side effects due to cancer chemotherapy or occurring as in response to organ transplantation.
摘要翻译：本发明涉及有效的细胞因子调节剂的新型肽。此外，本发明涉及包含药学上可接受的载体和细胞因子调节剂的药物组合物。向受试者施用这样的细胞因子调节剂可以增强或抑制细胞因子活性。因此，本发明提供一种调节受试者中细胞因子活性的方法，其特征在于异常或改变的细胞因子活性。本发明还提供了治疗这些病症的方法，包括例如废除解毒，由一氧化氮和细胞因子介导的疾病，药物不良反应，肥胖症，败血性休克以及由于癌症化学疗法或作为对器官的反应而发生的不良副作用移植。

8. 发明授权

US5658889A Method and compounds for aica riboside delivery and for lowering blood glucose 失效
标题翻译：用于阿ica核糖苷递送和降低血糖的方法和化合物
公开(公告)号：US5658889A
公开(公告)日：1997-08-19
申请号：US355836
申请日：1994-12-14
申请人： Harry E. Gruber , Ronald R. Tuttle , Clinton E. Browne , Bheemarao G. Ugarkar , Jack W. Reich , Ernest K. Metzner , Paul J. Marangos
发明人： Harry E. Gruber , Ronald R. Tuttle , Clinton E. Browne , Bheemarao G. Ugarkar , Jack W. Reich , Ernest K. Metzner , Paul J. Marangos
IPC分类号： A61K31/00 , A61K31/7056 , C07H19/052 , A61K31/70
CPC分类号： A61K31/7076 , A61K31/00 , A61K31/7056 , C07H19/052 , Y10S514/866
摘要： AICA riboside and prodrugs of AICA riboside are provided which lower blood glucose for the treatment of various pathologic conditions, including hypoglycemia, insulin deficiency, insulin resistance diabetes and Syndrome X. Prodrugs of AICA riboside provide AICA riboside in an orally bioavailable form. The use of adenosine kinase inhibition and ZMP enhancement for lowering blood glucose are also described.
摘要翻译：提供AICA核糖苷和AICA核糖苷的前药，其降低血糖用于治疗各种病理状况，包括低血糖，胰岛素缺乏，胰岛素抵抗性糖尿病和综合征X.AICA核苷的前体药物以口服生物可利用的形式提供AICA核糖苷。还描述了使用腺苷激酶抑制和ZMP增强来降低血糖。

9. 发明授权

US5395970A 1-(3,4-dihydroxyphenyl)-2-(4-(4-hydroxyphenyl)butaylamino)ethanol 失效
标题翻译： 1-（3,4-二羟基苯基）-2-（4-（4-羟基苯基）丁酰氨基）乙醇
公开(公告)号：US5395970A
公开(公告)日：1995-03-07
申请号：US169536
申请日：1993-12-15
申请人： Ronald R. Tuttle , Clinton E. Browne, III
发明人： Ronald R. Tuttle , Clinton E. Browne, III
IPC分类号： A61B5/00 , A61B10/00 , A61K31/135 , A61K31/16 , A61K31/165 , A61M1/00 , A61M37/00 , A61N1/30 , A61N1/32 , A61P9/00 , A61P9/10 , A61P25/02 , C07C45/30 , C07C215/60 , C07C217/62 , C07C237/30
CPC分类号： C07C237/30 , A61K31/135 , A61K31/16 , A61N1/044 , A61N1/30 , A61N1/325 , C07C215/60 , C07C217/62 , C07C45/305 , A61N1/0448 , Y10S128/13
摘要： Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.
摘要翻译：用于通过递送运动模拟剂的闭环药物递送系统来诊断，评估和治疗冠状动脉疾病（CAD）的方法和装置，包括引起急性和适应性心血管反应的新型运动模拟剂，其类似于那些提供有氧活动引发的。对运动模拟剂的急性反应用于诊断和评估CAD，代替对有氧运动的急性反应。由于其适应性反应，这些化合物可用于治疗CAD以代替由有氧运动训练引起的适应性反应或治疗其中需要有氧运动引起的适应性反应的其他状况。

10. 发明授权

US4511570A Senile dementia treatment 失效
标题翻译：老年痴呆症治疗
公开(公告)号：US4511570A
公开(公告)日：1985-04-16
申请号：US479638
申请日：1983-03-28
申请人： Ronald R. Tuttle
发明人： Ronald R. Tuttle
IPC分类号： A61K31/485
CPC分类号： A61K31/485 , Y10S514/879
摘要： A method is provided for orally treating a patient suffering from senile dementia which comprises the periodic oral delivery of a pharmaceutically effective amount of 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphone to said patient, whereby the patient tends to reduce his food intake. Also provided is an oral sustained release dosage unit form suitable for treating a patient suffering from obesity which permits a prolonged interval between administration to said patient, said oral dosage unit formulation comprising a plurality of granules which together constitute a pharmaceutically effective amount of 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphone to provide a sustained action over said prolonged interval, said plurality of granules each comprising a polymeric matrix to permit a substantially even release of said 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphone to permit the necessary sustained release over the prolonged period of time.
摘要翻译：提供了一种用于口服治疗患有老年痴呆症的患者的方法，其包括向所述患者定期口服递送药物有效量的6-亚甲基-6-脱氧-N-环丙基甲基-14-羟基二氢吗啡酮，由此患者倾向于减少他的食物摄入。还提供了适合于治疗患有肥胖症的患者的口服持续释放剂量单位形式，其允许在施用所述患者之间延长间隔，所述口服剂量单位制剂包含多个颗粒，其一起构成药学有效量的6-亚甲基 -6-脱氧-N-环丙基甲基-14-羟基二氢吗啉酮以提供在所述延长的间隔上的持续作用，所述多个颗粒各自包含聚合物基质，以允许基本均匀地释放所述6-亚甲基-6-脱氧-N-环丙基甲基 -14-羟基二氢吗啡酮，以允许在长时间内必需的持续释放。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式